[1]
Newberg, A.B., Wintering, N.A., Pl?ssl, K., Hochold, J., Stabin, M.G., Watson, M., Skovronsky, D., Clark, C.M., Kung, M.P. and Kung, H.F. (2006) Safety, Biodistribution, and Dosimetry of 123I-IMPY: A Novel Amyloid Plaque- Imaging Agent for the Diagnosis of Alzheimer’s Disease. J Nucl Med., 47, 748-754.
[2]
Reiman, E.M., Uecker, A., Gonzalez-Lima, F., Minear, D., Chen, K., Callaway, N.L., Berndt, J.D. and Games, D. (2000) Tracking Alzheimer’s Disease in Transgenic Mice Using Fluorodeoxyglucose Autoradiography. Neuroreport, 11, 987-991.
http://dx.doi.org/10.1097/00001756-200004070-00018
[3]
Lee, C.W., Kung, M.P., Hou, C. and Kung, H.F. (2003) Dimethylamino-Fluorenes: Ligands for Detecting β-Amyloid Plaques in the Brain. Nucl Med Biol., 30, 573-580.
http://dx.doi.org/10.1016/S0969-8051(03)00050-7
[4]
Nakamura, S., Murayama, N., Noshita, T., Annoura, H. and Ohno, T. (2001) Progressive Brain Dysfunction Following Intracerebroventricular Infusion of Beta1-42-Amyloid Pep-tide. Brain Res., 912, 128-136.
http://dx.doi.org/10.1016/S0006-8993(01)02704-4
[5]
Lockhart, A. (2006) Imaging Alzheimer’s Disease Pathology: One Target, Many Ligands. Drug Discov Today, 11, 1093-1099.
http://dx.doi.org/10.1016/j.drudis.2006.10.008
[6]
Routtenberg, A. (1997) Measuring Memory in a Mouse Model of Alzheimer’s Disease. Science, 277, 839-841.
http://dx.doi.org/10.1126/science.277.5327.839
[7]
Barrios, J.R., Kepea, V., Satyamurthy, N., Huang, S.C. and Gary, W. (2006) Brain Pathology and Neuronal Losses in the Living Brain of Alzheimer’s Patients. Int Congr Ser., 1290, 150-155.
http://dx.doi.org/10.1016/j.ics.2005.11.102
[8]
Giovannelli, L., Casamenti, F., Scali, C., Bartolini, L. and Pepeu, G. (1995) Differential Effects of Amyloid Peptides β-(1-40) and β-(25-35) Injections into the Rat Nucleus Basalis. Neuroscience, 66, 781-792.
http://dx.doi.org/10.1016/0306-4522(94)00610-H
[9]
Liu, J., Kepe, V., Zabjek, A., Petric, A., Padgett, H.C., Satya-murthy, N. and Barrio, J.R. (2007) High-Yield, Automated Radiosynthesis of 2-(1-{6-[(2-[18F]Fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) Ready for Animal or Human Administration. Mol Imaging Biol., 9, 6-16.
http://dx.doi.org/10.1007/s11307-006-0061-4
[10]
Agdeppa, E.D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cole, G.M., Small, G.W., Huang, S.C. and Barrio, J.R. (2001) Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer’s Disease. J Neurosci., 21, RC189.
[11]
Agdeppa, E.D., Kepe, V., Liu, J., Small, G.W., Huang, S.C., Petric, A., Satyamurthy, N. and Barrio, J.R. (2003) 2-Dialkylamino-6-acylmalononitrile Substituted Naphthalenes (DDNP Analogs): Novel Diagnostic and Thera-peutic Tools in Alzheimer’s Disease. Mol Imaging Biol., 5, 404-417.
http://dx.doi.org/10.1016/j.mibio.2003.09.010
[12]
Kung, H.F., Kung, M.P., Zhuang, Z.P., Hou, C., Lee, C.W., Pl?ssl, K., Zhuang, B., Skovronsky, D.M., Lee, V.M. and Trojanowski, J.Q. (2003) Iodinated Tracers for Imaging Amyloid Plaques in the Brain. Mol Imaging Biol., 5, 418-426.
http://dx.doi.org/10.1016/j.mibio.2003.09.003
